HCV treatment of special populations: HIV coinfected, liver transplant, and renal failure

Clinical Liver Disease

Volumn 4, Issue 4, 2014, Pages 80-83

  Anwar, Nadeem ^a   Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BOCEPREVIR; DACLATASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REDUCTION; FOOD AND DRUG ADMINISTRATION; GRAFT RECIPIENT; HEPATITIS C; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84911123496     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.397     Document Type: Review

References (16)

1. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann of Intern Med 2012;157:817-822.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837
4. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. NEJM 2004;351:438-450.
5. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, AIDS Clinical Trials Group A5071 Study Team, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
6. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, ANRS HCO2 RIBAVIC Study Team, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848.
7. Sulkowski M, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159:86-96.
8. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double blind, controlled phase 2 trial. Lancet Infect Dis 2013;13:597-605.
9. Hare CB, Sherman KE, Talal A, Tebas P, Bsharat M, Friedman M, Rockstroh JK. Simplified dosing and response-guided therapy using telaprevir combination treatment for genotype 1 HCV treatment naïve or -experienced HIV co-infected patients: UNITE Interim Analysis. In HepDART 2013, Big Island, Hawaii, 2013: Abstract no. 64.
10. Rodriguez-Torres M, Gonzalez A, Rodriguez J, et al., Sofosbuvir and Peginterferon alfa-2a/RibavirinTreatment of naïve Genotype 1-4 HCV infected patients that are co-infected with HIV. In Proceedings ID Week 2013. San Francisco, CA, 2013: Abstract no.714.
11. Sulkowski M, Rodriguez-Torres M, Lalezari J, Fessel W, Mounzer K, Shuhart M, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). In Proceedings 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, 2013: Abstract no. 66.
12. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004;4(suppl 1):S31-S38.
13. Saxena V, Manos MM, Yee HS, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther 2014;39:1213-1224.
14. Samuel D, Charlton M, Gane E, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. In Proceedings 49thEuropean Association for the Study of the Liver International Liver Congress (EASL 2014). London, UK, 2014: Abstract P.1232.
15. Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013;159:729-738.
16. Dumortier J1, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013;56:146-149.